We understand that hearing the term “triple-negative” in relation to a breast cancer diagnosis can feel unsettling and bring many questions. This specific type of breast cancer presents unique challenges, but it is important to know that significant progress is being made in its treatment. Our commitment is to provide you with clear, professional, and compassionate information to help you understand what triple-negative breast cancer (TNBC) is, who is at risk, and what the current treatment landscape looks like. We want you to feel informed and supported as you learn about this condition. Visit the best Women’s Health Clinic in Brooklyn at Doral Health & Wellness, or log on to www.doralhw.org.
What is Triple-Negative Breast Cancer?
Triple-negative breast cancer is a type of invasive breast cancer that accounts for about 10-15% of all diagnoses. The “triple-negative” name means that the cancer cells test negative for three key receptors that are commonly found on breast cancer cells: estrogen receptors, progesterone receptors, and excess HER2 (human epidermal growth factor receptor 2) protein.
We recognize that this distinction is critical because it dictates treatment options. Many common breast cancer treatments, such as hormone therapy and drugs that target HER2, are designed to work by blocking these receptors. Since TNBC cells lack these targets, those therapies are not effective. This is why treatment for TNBC typically involves chemotherapy and, more recently, other innovative approaches like immunotherapy.
Key Characteristics of TNBC
We want you to be aware of the characteristics that make this type of breast cancer different:
- Aggressive Nature: TNBC tends to grow and spread more quickly than other types of breast cancer.
- Higher Recurrence Risk: There is a higher likelihood of the cancer returning after treatment, especially within the first few years.
- Unique Demographics: It is more common in women under the age of 40, African American women, and individuals with a BRCA1 gene mutation.
Elevating breast cancer health awareness about these specific traits is crucial for early detection and effective management.
Who is at Risk for Triple-Negative Breast Cancer?
While any person can develop TNBC, we know that certain factors can increase your risk. Understanding these risk factors is an important part of proactive health management.
- Age: TNBC is more frequently diagnosed in women younger than 40.
- Genetics: Having a mutation in the BRCA1 gene is strongly linked to an increased risk of developing triple-negative breast cancer.
- Race and Ethnicity: We understand that African American and Hispanic women have a higher incidence of TNBC compared to women of other ethnicities.
- Family History: A strong family history of breast cancer, particularly diagnoses at a young age, can increase your risk.
If you have one or more of these risk factors, it is important to speak with your healthcare provider about a personalized screening plan.
How is Triple-Negative Breast Cancer Treated?
Because TNBC lacks the common receptors targeted by hormonal therapies, the treatment approach is different. We are here to provide clear information on the primary treatment strategies.
- Chemotherapy
Chemotherapy remains the cornerstone of treatment for triple-negative breast cancer. It is often used in several different settings:
- Neoadjuvant Chemotherapy: Given before surgery to shrink the tumor, making it easier to remove and providing information on how well the cancer responds to treatment.
- Adjuvant Chemotherapy: Given after surgery to eliminate any remaining cancer cells and reduce the risk of recurrence.
- Surgery
Surgery is a standard part of treatment, either in the form of a lumpectomy (removing the tumor and a small margin of surrounding tissue) or a mastectomy (removing the entire breast). The type of surgery recommended depends on the tumor size, location, and other individual factors.
- Radiation Therapy
Radiation therapy is often recommended after surgery, especially after a lumpectomy, to destroy any cancer cells that may have been left behind in the breast area.
- PARP Inhibitors and Immunotherapy
Recent advancements have introduced more targeted options for certain patients with TNBC.
- PARP Inhibitors: For patients with a BRCA gene mutation, drugs called PARP inhibitors can be effective. These drugs block a protein that helps cancer cells repair their DNA, causing them to die.
- Immunotherapy: For some advanced TNBC tumors that express the PD-L1 protein, immunotherapy can be used. These drugs help the body’s own immune system recognize and attack the cancer cells.
Your Partner in Health and Wellness
We believe that knowledge and proactive care are powerful tools. Understanding the specifics of triple-negative breast cancer empowers you to have more informed conversations with your healthcare team. Continuous research is paving the way for more effective and personalized treatments, offering new hope for patients. Promoting breast cancer health awareness ensures that more individuals understand their risk and the importance of early detection. Please navigate here to learn more about our Breast cancer warriors.
We are committed to providing you with the highest level of compassionate and professional care. It is essential to work closely with an oncology team to create a treatment plan tailored to your unique situation. If you have questions or need support, we encourage you to contact Doral Health & Wellness. For further inquiries, call us on +1- 718-367-2555 to get a consultation. We have some of the finest health specialists who listen to your concerns, examine your symptoms, and create a treatment plan to improve your condition as soon as possible. Log on to www.doralw.org. Or visit us at 1797 Pitkin Avenue, Brooklyn, NY 11212.
